Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Composición farmacéutica para tratamiento y prevención de enfermedades del hígado

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOKR20150807001
Publicado:
18/08/2015
Caducidad:
17/08/2016
Resumen:
Una importante universidad coreana ha descubierto una composición farmacéutica para el tratamiento y prevención de enfermedades del hígado, especialmente la enfermedad por hígado graso no alcohólico, hepatitis y cirrosis. La composición incluye ingredientes activos, como precursor de plasmalógeno, plasmalógeno y análogo de plasmalógeno y reduce la acumulación de triglicéridos, inhibiendo la expresión génica inflamatoria de citoquinas. Se buscan compañías farmacéuticas en Europa para licenciar la tecnología.

Details

Tittle:
Korean university offering pharmaceutical composition for treating or preventing liver diseases.
Summary:
One of the prominent universities in South Korea has found pharmaceutical composition for treating or preventing liver diseases, especially non-alcoholic fatty liver disease. The composition includes active constituents such as plasmalogen precursor, plasmalogen, and plasmalogen analogue. This gives effects on decreasing hepatic triglyceride accumulation, inhibiting inflammatory cytokine gene expression. The university is seeking a European pharmaceutical company to license its technology.
Description:
The liver in a human body plays an important role in many bodily functions from protein production and blood clotting to cholesterol, glucose and iron metabolism.
Liver disease can be caused by a variety of factors that damage the liver and it can lead to liver failure. Liver failure can occur gradually or suddenly, but sadly,when liver failure occurs it needs urgent medical care since it is a life-threatening condition. In modern medical technology, there is only treatment for acute liver failure.

In the meantime, this Korean university, which is prominent for its medical college, has found pharmaceutical composition including plasmalogen precursor, plasmalogen, plasmalogen analogue which can decrease triglyceride accumulation in hepatic tissue cells and inhibit inflammatory cytokine gene expression. Additionally, it can increase fatty acid oxidation through peroxisomes. With this composition, medicine or health supplements for the purpose of preventing or treating liver disease could be made.

Plasmalogen precursor is alkoxy glycerol which backbone is bonded to fatty alcohol C16 or C18 via an ether linkage. Here, alkoxy glycerol is similar to shark liver oil(squalene) composed of batyl alcohol, chimyl alcohol, and selachyl alcohol. The university conducted an experiment to prove the effectiveness of this composition, and concluded that it really reduces lipid content of the liver and help liver not become a fatty liver. The main components are composed of healthy components that are proved to be safe and are mainly used to prevent and treat fatty livers.

The university is looking for a partner who can license in its technology to localize in the partner´s area. It is particularly seeking a pharmaceutical company or other related companies.
Advantages and Innovations:
- Decreasing hepatic triglyceride accumulation
- Inhibiting inflammatory cytokine gene expression
- By increasing fatty acid oxidation, it can treat liver disease such as fatty liver(especialy non-alcohol fatty liver), hepatitis, or liver cirrhosis
Stage of Development:
Available for demonstration
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Korean patent and PCT applied but not yet granted

Partner sought

Type and Role of Partner Sought:
- Type of partner sought : companies
- Specific area of activity of the partner : global pharmaceutical companies
- Task to be performed : The university seeks a European partner to achieve licensing agreement on localization of its technology

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English

Keywords

Technology Keywords:
06001005 Diagnósticos, diagnosis
06001015 Productos farmacéuticos / medicamentos